Appropriate dosing of burosumab in tumor-induced osteomalacia

Osteoporos Int. 2023 Feb;34(2):421. doi: 10.1007/s00198-022-06617-2. Epub 2022 Dec 1.

Authors

Luciano Colangelo¹, Chiara Sonato¹, Mara Riminucci², Alessandro Corsi³, Salvatore Minisola¹

Affiliations

¹ Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
² Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
³ Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. alessandro.corsi@uniroma1.it.

PMID: 36454246
DOI: 10.1007/s00198-022-06617-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / therapeutic use
Familial Hypophosphatemic Rickets*
Fibroblast Growth Factors
Humans
Osteomalacia* / drug therapy

Substances

burosumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal
Fibroblast Growth Factors

Supplementary concepts

Oncogenic osteomalacia